Natco just can’t kick its high-risk, high-gain game plan

CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?

03 October, 202412 min
0
Natco just can’t kick its high-risk, high-gain game plan

You may also like

Business
Story image

Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?

The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.

Health
Story image

Indian pharma exporters protesting against new regulations is not a good look

The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.

Internet
Story image

Why is Swiggy catching flak for its latest quick-delivery promise?

The food and grocery delivery company’s idea of providing prescription drugs in 10 minutes is facing resistance from traditional pharma players.